10X Genomics Inc logo

TXG - 10X Genomics Inc Share Price

$143.79 7.2  5.3%

Last Trade - 14/05/21

Large Cap
Market Cap £11.20bn
Enterprise Value £10.76bn
Revenue £236.1m
Position in Universe 712th / 6846
Unlock TXG Revenue
Relative Strength (%)
1m -24.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -29.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 71.1 146.3 245.9 298.8 497.4 679.8 +61.4%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, 10XGenomics Inc revenues increased 47% to $105.8M. Net lossdecreased 45% to $11.6M. Revenues reflect Consumablessegment increase of 52% to $93.1M, Instruments segmentincrease of 22% to $11.1M, China segment increase from $11Mto $23.6M, Northern America segment increase of 30% to$51.8M. Lower net loss reflects Loss on extinguishment ofdebt decrease from $1.5M (expense) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for TXG
Graphical History


TXG Revenue Unlock TXG Revenue

Net Income

TXG Net Income Unlock TXG Revenue

Normalised EPS

TXG Normalised EPS Unlock TXG Revenue

PE Ratio Range

TXG PE Ratio Range Unlock TXG Revenue

Dividend Yield Range

TXG Dividend Yield Range Unlock TXG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
TXG EPS Forecasts Unlock TXG Revenue
Profile Summary

10x Genomics, Inc. is a life science technology company. The Company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The Company’s product consists of chromium single cell gene expression solution, cell immune profiling solution, cell copy number variation (CNV) solution, Cell assay for transposase accessible chromatin (ATAC) solution. The Company’s Chromium platform enables analysis of individual biological components, such as up to millions of single cells. Its Visium platform is designed to identify where biological components are located and how they are arranged with respect to each other. Its molecular assays are used with its Chromium platform, and with its planned Visium platform, to provide sensitive and robust biochemistries that convert minute amounts of biological analytes into detectable signals.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: 60
No. of Employees: 946
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 109,799,289
Free Float (0.0%)
Eligible for
TXG Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TXG
Upcoming Events for TXG
Friday 11th June, 2021
10X Genomics Inc Annual Shareholders Meeting
Tuesday 15th June, 2021 Estimate
10X Genomics Inc Annual Shareholders Meeting
Wednesday 4th August, 2021 Estimate
Q2 2021 10X Genomics Inc Earnings Release
Monday 8th November, 2021 Estimate
Q3 2021 10X Genomics Inc Earnings Release
Frequently Asked Questions for 10X Genomics Inc
What is the 10X Genomics Inc share price?

As of 14/05/21, shares in 10X Genomics Inc are trading at $143.79, giving the company a market capitalisation of £11.20bn. This share price information is delayed by 15 minutes.

How has the 10X Genomics Inc share price performed this year?

Shares in 10X Genomics Inc are currently trading at $143.79 and the price has moved by 82.08% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the 10X Genomics Inc price has moved by 26.79% over the past year.

What are the analyst and broker recommendations for 10X Genomics Inc?

There are no analysts currently covering 10X Genomics Inc.

When will 10X Genomics Inc next release its financial results?

10X Genomics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the 10X Genomics Inc dividend yield?

10X Genomics Inc does not currently pay a dividend.

Does 10X Genomics Inc pay a dividend?

10X Genomics Inc does not currently pay a dividend.

When does 10X Genomics Inc next pay dividends?

10X Genomics Inc does not currently pay a dividend.

How do I buy 10X Genomics Inc shares?

To buy shares in 10X Genomics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of 10X Genomics Inc?

Shares in 10X Genomics Inc are currently trading at $143.79, giving the company a market capitalisation of £11.20bn.

Where are 10X Genomics Inc shares listed? Where are 10X Genomics Inc shares listed?

Here are the trading details for 10X Genomics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: TXG
What kind of share is 10X Genomics Inc?

Based on an overall assessment of its quality, value and momentum, 10X Genomics Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a 10X Genomics Inc share price forecast 2021?

Shares in 10X Genomics Inc are currently priced at $143.79. At that level they are trading at 45.75% discount to the analyst consensus target price of 0.00.

Analysts covering 10X Genomics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.686 for the next financial year.

How can I tell whether the 10X Genomics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 10X Genomics Inc. Over the past six months, the relative strength of its shares against the market has been -8.47%. At the current price of $143.79, shares in 10X Genomics Inc are trading at -5.03% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the 10X Genomics Inc PE Ratio?

We were not able to find PE ratio data for 10X Genomics Inc.

Who are the key directors of 10X Genomics Inc?

10X Genomics Inc's management team is headed by:

John Stuelpnagel - CHM
Serge Saxonov - CEO
Benjamin Hindson - PRE
Justin McAnear - CFO
Bradford Crutchfield - CCO
Kimberly Popovits - IND
Sridhar Kosaraju - IND
Mathai Mammen - IND
Bryan Roberts - IND
Shehnaaz Suliman - IND
Eric Whitaker - GCN
Jean Philibert - CHO
Who are the major shareholders of 10X Genomics Inc?

Here are the top five shareholders of 10X Genomics Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 10.99% (9.59m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.48% (6.53m shares)
Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund
Percentage owned: 6.78% (5.92m shares)
Foresite Capital Management, LLC Private Equity
Percentage owned: 4.3% (3.75m shares)
ARK Investment Management LLC Investment Advisor
Percentage owned: 4.02% (3.50m shares)
Similar to TXG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.